Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – March 10, 2021 @ 4:00pm

Oklahoma Health Care Authority (OHCA) Webinar
Please register for the meeting at:
https://zoom.us/s/97305655255
After registering, you will receive a confirmation email containing information about joining the webinar.

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Mitchell, Vice Chairwoman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:	**Telephone Conference Participants**
Dr. Stephen Anderson –	participating via Zoom teleconference
Dr. Jennifer de los Angeles –	participating via Zoom teleconference
Ms. Jennifer Boyett –	participating via Zoom teleconference
Dr. Markita Broyles –	participating via Zoom teleconference
Dr. Theresa Garton –	participating via Zoom teleconference
Dr. Megan Hanner –	participating via Zoom teleconference
Dr. Lynn Mitchell –	participating via Zoom teleconference
Dr. John Muchmore –	participating via Zoom teleconference
Dr. Lee Muñoz –	participating via Zoom teleconference
Dr. James Osborne –	participating via Zoom teleconference

Public Access to Meeting via Zoom:

Please register for the meeting at:
https://zoom.us/s/97305655255

Or join by phone:
Dial: +1-253-215-8782 or +1-346-248-7799
Webinar ID: 973 0565 5255
Passcode: 92831084

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to *DURPublicComment@okhca.org*. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Mitchell, Vice Chairwoman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Mitchell, Vice Chairwoman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. February 17, 2021 DUR Minutes – Vote
B. February 17, 2021 DUR Recommendation Memorandum
C. Correspondence

Items to be presented by Dr. Smith, Dr. Mitchell, Vice Chairwoman:

4. Quarterly Review of the Medication Therapy Management (MTM) Program – See Appendix B

A. Medication Therapy Management Program Update

Items to be presented by Dr. Nawaz, Dr. Wilson, Dr. Mitchell, Vice Chairwoman:

5. Update on Medication Coverage Authorization Unit/Spring 2021 Pipeline Update – See Appendix C

A. Pharmacy Helpdesk Activity for February 2021
B. Medication Coverage Activity for February 2021
C. Spring 2021 Pipeline Update

Items to be presented by Dr. Wilson, Dr. Mitchell, Vice Chairwoman:

6. Action Item – Vote to Prior Authorize Anjeso® (Meloxicam Injection) and Licart™ (Diclofenac Epolamine Topical System) – See Appendix D

A. New U.S. Food and Drug Administration (FDA) Approval(s)
B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Mitchell, Vice Chairwoman:

7. Action Item – Vote to Prior Authorize Oxlumo™ (Lumasiran) – See Appendix E

A. Introduction
B. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Mitchell, Vice Chairwoman:

8. Action Item – Vote to Prior Authorize Fintepla® (Fenfluramine) – See Appendix F

A. New U.S. Food and Drug Administration (FDA) Approval(s)
B. College of Pharmacy Recommendations

Items to be presented by Dr. Daniel, Dr. Mitchell, Vice Chairwoman:

9. Action Item – Vote to Prior Authorize Teriparatide – See Appendix G

A. Introduction
B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Mitchell, Vice Chairwoman:

10. Action Item – Vote to Prior Authorize Zokinvy™ (Lonafarnib) – See Appendix H

A. Introduction
B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Mitchell, Vice Chairwoman:

11. Action Item – Vote to Prior Authorize Nurtec™ ODT (Rimegepant) and Vyepti® (Eptinezumab-jjmr) – See Appendix I

A. Introduction
B. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Mitchell, Vice Chairwoman:

12. Action Item – Vote to Prior Authorize Inqovi® (Decitabine/Cedazuridine), Onureg® (Azacitidine), and Riabni™ (Rituximab-arrx) – See Appendix J

A. Introduction
B. New U.S. Food and Drug Administration (FDA) Approval(s) and Indication(s)

C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Mitchell, Vice Chairwoman:

13. Action Item – Annual Review of Qutenza® (Capsaicin 8% Patch) – See Appendix K

A. Current Prior Authorization Criteria
B. Utilization of Qutenza® (Capsaicin 8% Patch)
C. Prior Authorization of Qutenza® (Capsaicin 8% Patch)
D. Market News and Updates
E. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Mitchell, Vice Chairwoman:

14. Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Breyanzi® (Lisocabtagene Maraleucel), Monjuvi® (Tafasitamab-cxix), Romidepsin 27.5mg/5.5mL Vial, Tecartus™ (Brexucabtagene Autoleucel), and Ukoniq™ (Umbralisib) – See Appendix L

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Lymphoma Medications
D. Prior Authorization of Lymphoma Medications
E. Market News and Updates
F. Product Summaries
G. College of Pharmacy Recommendations
H. Utilization of Lymphoma Medications

Items to be presented by Dr. Borders, Dr. Mitchell, Vice Chairwoman:

15. Annual Review of Lutathera® (Lutetium Lu 177 Dotatate) and Vitrakvi® (Larotrectinib) – See Appendix M

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib)
D. Prior Authorization of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib)
E. Market News and Updates
F. College of Pharmacy Recommendations

Items to be presented by Dr. Ratterman, Dr. Mitchell, Vice Chairwoman:

16. Annual Review of Hemophilia Medications and 30-Day Notice to Prior Authorize Sevenfact® [Coagulation Factor VIIA (Recombinant)-jncw] – See Appendix N

A. Current Prior Authorization Criteria
B. Utilization of Hemophilia Medications
C. Prior Authorization of Hemophilia Medications
D. Market News and Updates
E. Sevenfact® [Coagulation Factor VIIA (Recombinant)-jncw] Product Summary
F. Cost Comparison
G. College of Pharmacy Recommendations
H. Utilization Details of Hemophilia Medications

Items to be presented by Dr. Nawaz, Dr. Mitchell, Vice Chairwoman:

17. Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Bafiertam™ (Monomethyl Fumarate), Kesimpta® (Ofatumumab), and Zeposia® (Ozanimod) – See Appendix O

A. Current Prior Authorization Criteria
B. Utilization of MS Medications
C. Prior Authorization of MS Medications
D. Market News and Updates

E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of MS Medications

Items to be presented by Dr. Chandler, Dr. Mitchell, Vice Chairwoman:

18. Annual Review of Hereditary Angioedema (HAE) Medications and 30-Day Notice to Prior Authorize Orladeyo™ (Berotralstat) – See Appendix P

A. Current Prior Authorization Criteria
B. Utilization of HAE Medications
C. Prior Authorization of HAE Medications
D. Market News and Updates
E. Orladeyo™ (Berotralstat) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of HAE Medications

Items to be presented by Dr. Ha, Dr. Mitchell, Vice Chairwoman:

19. Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and 30-Day Notice to Prior Authorize Nyvepria™ (Pegfilgrastim-apgf) – See Appendix Q

A. Current Prior Authorization Criteria
B. Utilization of G-CSFs
C. Prior Authorization of G-CSFs
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of G-CSFs

Items to be presented by Dr. Ha, Dr. Mitchell, Vice Chairwoman:

20. Annual Review of Anti-Emetic Medications and 30-Day Notice to Prior Authorize Barhemsys® (Amisulpride) – See Appendix R

A. Current Prior Authorization Criteria
B. Utilization of Anti-Emetic Medications
C. Prior Authorization of Anti-Emetic Medications
D. Market News and Updates
E. Barhemsys® (Amisulpride) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Anti-Emetic Medications

Items to be presented by Dr. Wilson, Dr. Mitchell, Vice Chairwoman:

21. Annual Review of Growth Hormone Products and 30-Day Notice to Prior Authorize Sogroya® (Somapacitan-beco) – See Appendix S

A. Current Prior Authorization Criteria
B. Utilization of Growth Hormone Products
C. Prior Authorization of Growth Hormone Products
D. Market News and Updates
E. Sogroya® (Somapacitan-beco) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Growth Hormone Products

Items to be presented by Dr. Nawaz, Dr. Mitchell, Vice Chairwoman:

22. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix T

Items to be presented by Dr. Adams, Dr. Mitchell, Vice Chairwoman:

23. Future Business* (Upcoming Product and Class Reviews)

A. Annual Review of the Pharmacy Benefit
B. Anti-Diabetic Medications

C. Antihypertensive Medications
D. Muscular Dystrophy Medications
**Future product and class reviews subject to change.*

24. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.